Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galena spins-out RXi, which gets $9.5mm in funding from investors

Executive Summary

RXi Pharmaceuticals Corp. is splitting into two publicly traded companies: Galena Biopharma Inc. will focus on cancer therapeutics while the new RXi will spin off and continue the former company’s work on RNAi. In connection with the partial spin-off, two institutional investors purchased $9.5mm of RXi’s Series A preferred shares, an amount which includes shares converted from a $1.5mm bridge loan.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Preliminary
Deal Type
  • Financing
    • Convertible Debt
    • Other
    • Private Investment in Public Equity
    • Private Placement
    • Spin-Off

Related Companies